List of Tables
Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES 12
Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES 14
Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES 19
Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2016 19
Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma 27
Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2016 29
Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2016 30
Table 8: Ophthalmology Therapeutics Market, Global, Approved Indications for Avastin, 2016 32
Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2016 33
Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2016 35
Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2016 36
Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2016 37
Table 13: Ophthalmology, Global, Annual Revenue Forecast for key Products ($bn), 2015-2022 61
Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2015–2022 73
Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2016 93
Table 16: Ophthalmology Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006–2015 98
Table 17: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 107